Insider Trades of KIRK RANDAL J Information

Click on the column header to resort ascending (▲) or descending (▼).

Individual Insider Trades

Company Relation Last Date ▲ Type Tran OwnerType Shares Traded Last Price Shares Held
ORAGENICS INC Beneficial Owner (10%) 09/30/2013 Form 4 Buy indirect 2,648,510 3 7,898,490
FIBROCELL SCIENCE, INC. Beneficial Owner (10%) 10/01/2013 Form 4 Buy indirect 3,658,536 4.1 14,219,837
ZIOPHARM ONCOLOGY INC Director 10/29/2013 Form 4 Buy indirect 2,857,143 3.5 17,736,767
ORAGENICS INC Beneficial Owner (10%) 11/20/2013 Form 4 Buy indirect 1,242,490 2.5 9,140,980
SYNTHETIC BIOLOGICS, INC. Beneficial Owner (10%) 12/17/2013 Form 4 Buy indirect 2,500,000 1 12,300,768
ORAGENICS INC Beneficial Owner (10%) 12/18/2013 Form 4 Acquisition (Non Open Market) indirect 698,241 2.82 9,839,221
ZIOPHARM ONCOLOGY INC Director 12/31/2013 Form 4 Acquisition (Non Open Market) direct 18,818 0 78,941
FIBROCELL SCIENCE, INC. Beneficial Owner (10%) 01/24/2014 Form 4 Buy indirect 1,024,590 4.88 15,244,427
INTREXON CORP Officer 03/27/2014 Form 4 Buy indirect 243,001 25.72 62,566,907
INTREXON CORP Officer 05/09/2014 Form 4 Buy indirect 15,088 13.42 779,294
INTREXON CORP Officer 05/12/2014 Form 4 Buy indirect 18,066 15.89 797,360
INTREXON CORP Officer 05/13/2014 Form 4 Buy indirect 32,019 15.63 62,632,080
HALOZYME THERAPEUTICS INC Director 05/13/2014 Form 4 Acquisition (Non Open Market) direct 24,876 0 3,504,876
FIBROCELL SCIENCE, INC. Beneficial Owner (10%) 06/04/2014 Form 4 Buy indirect 400,000 2.9 15,644,427
ZIOPHARM ONCOLOGY INC Director 12/31/2014 Form 4 Acquisition (Non Open Market) direct 16,707 0 95,648
INTREXON CORP Officer 12/31/2014 Form 4 Disposition (Non Open Market) indirect 1,679,578 0
INTREXON CORP Officer 12/31/2014 Form 4 Acquisition (Non Open Market) indirect 344,258 0 61,169,126
INTREXON CORP Officer 01/27/2015 Form 4 Buy indirect 555,556 27 61,724,682
ZIOPHARM ONCOLOGY INC Director 02/09/2015 Form 4 Buy indirect 1,440,000 8.75 19,176,767
HALOZYME THERAPEUTICS INC Director 05/06/2015 Form 4 Acquisition (Non Open Market) direct 13,175 0 3,518,051